| Market Capitalization (Millions $) |
77 |
| Shares
Outstanding (Millions) |
62 |
| Employees |
24 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-48 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Galectin Therapeutics Inc
Galectin Therapeutics Inc is a publicly traded, clinical-stage biotechnology company that is focused on developing therapies to treat fibrosis and cancer. In particular, the company is working on developing galectin inhibitors, which are drugs designed to block the activity of galectins, which are proteins involved in inflammation, cell growth, and cell death.
The company was founded in 2000 and is based in Norcross, Georgia. Its lead product candidate is GR-MD-02, a galectin-3 inhibitor that is being developed to treat a variety of fibrotic diseases, including non-alcoholic steatohepatitis (NASH), or fatty liver disease, and liver fibrosis caused by hepatitis C virus (HCV) infection. The company is also exploring the use of galectin inhibitors to treat various types of cancer.
Galectin has completed multiple clinical trials of GR-MD-02 for NASH and liver fibrosis, including a phase 2b clinical trial of GR-MD-02 in patients with NASH cirrhosis. The company is currently conducting a phase 2 clinical trial of GR-MD-02 in combination with KEYTRUDA for the treatment of metastatic melanoma.
In addition to GR-MD-02, Galectin has a pipeline of galectin inhibitors in various stages of development, including GR-e, a galectin-1 inhibitor being developed for the treatment of cancer, and GM-CT-01, a galectin-9 inhibitor being developed for the treatment of asthma and other inflammatory diseases.
Overall, Galectin Therapeutics is focused on developing innovative therapies for serious diseases with unmet medical needs, particularly fibrotic diseases and cancer.
Company Address: 4960 Peachtree Industrial Blvd. Norcross 30071 GA
Company Phone Number: 620 -3186 Stock Exchange / Ticker: NASDAQ GALT
|
8.37% 